Skip to main

Payment Policy

ASGCT supports payment policies that facilitate patient access to approved cell and gene therapies, including full coverage to FDA-labeled indications, appropriate reimbursement for providers, and the development of innovative payment mechanisms.

Advocating for Fair Payment Policies

ASGCT’s mission is to advance the discovery and clinical application of genetic and cellular therapies to alleviate human disease. A strategic priority of the Society is advocating to policymakers for maximal patient access to approved cell and gene therapies (CGTs), which includes support of payment policies that facilitate such access. The unique one-time, potentially curative nature of many CGTs render them highly valuable, but with associated upfront costs that pose challenges to some payers within the current healthcare system. 

The Society supports full coverage and sufficient provider reimbursement for approved therapies, as well as payment models that foster patient access. These positions do not imply endorsement of any individual pricing decisions. More specifically, ASGCT supports the following policies: 

  • Expedient coverage of gene and cell therapies to their full FDA-labelled indications. State Medicaid programs often do not have publicly-available coverage policies, and those that do frequently have coverage restrictions.
  • Reform of the Medicare Inpatient Prospective Payment System to adequately reimburse providers.  
  • Enabling of value-based payment over time or outcomes-based arrangements that link reimbursement to demonstrated durability and real-world effectiveness. These models can increase payer confidence in covering cell and gene therapies by providing financial protection when treatments do not achieve expected long-term outcomes, while maintaining appropriate patient access to approved therapies. Legal and regulatory barriers currently exist that can limit or prevent use of these payment models.

Resources  

Committee Involvement

The Government Relations Committee develops relationships with government entities, including the NIH, Congress, and CMS. The duties of the committee include recommending policy positions that support gene and cell therapy research, development, and access, as well as responsible use of these technologies; and recommending educational programming that addresses major policy issues in the field.

ASGCT Committees

Collaborative Efforts